William D. Waddill - 06 Feb 2026 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Director
Signature
/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill
Issuer symbol
PTGX
Transactions as of
06 Feb 2026
Net transactions value
-$1,507,400
Form type
4
Filing time
06 Feb 2026, 16:38:54 UTC
Previous filing
06 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Waddill William D. Director C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK /s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill 06 Feb 2026 0001553338

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $166,200 +20,000 +256% $8.31 27,825 06 Feb 2026 Direct
transaction PTGX Common Stock Sale $1,673,600 -20,000 -72% $83.68 7,825 06 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -20,000 -100% $0.000000 0 06 Feb 2026 Common Stock 20,000 $8.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.65 to $83.87. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2 These stock options are fully vested.